India Glycols Limited has informed the Exchange about Investor Presentation
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
India Glycols reported a strong Q1 FY26 with Net Revenue up 7.4% YoY to ₹1,040 Cr, EBITDA up 17.7% to ₹151 Cr, and PAT up 21.3% to ₹73 Cr. EBITDA margin expanded 128 bps to 14.5% and PAT margin rose 80 bps to 7.0%, driven by Potable Spirits (PS) and Bio-based Specialties (BSPC) segments. Bio-Fuel revenue surged 45.4% YoY to ₹348 Cr, supported by India's ethanol blending program (18.6% achieved, targeting 20% by ESY 25-26). The company announced a 1:1 stock split with record date of August 12, 2025, and a proposed demerger of the Potable Spirits/Bio-Fuel business into IGL Spirits Limited and the Bio-Pharma business into Ennature Bio Pharma Limited, both of which will be separately listed. The Ennature Biopharma segment continued to face headwinds, with revenue declining 11.1% YoY and EBIT margin falling to 2.4%.
Positive for shareholders — strong quarterly earnings beat, healthy margin expansion, and the proposed three-way demerger could unlock value by giving each business a clear strategic focus and attracting focused sector investors. The stock split improves liquidity for retail participation.